Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196
Intrinsic Value
Shanghai Fosun Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. [ Read More ]
The intrinsic value of one
Shanghai Fosun Pharmaceutical Group Co Ltd
stock under the Base Case scenario is
40.28
CNY.
Compared to the current market price of 24.12 CNY,
Shanghai Fosun Pharmaceutical Group Co Ltd
is
Undervalued by 40%.
Shanghai Fosun Pharmaceutical Group Co Ltd's market capitalization is 64.4B CNY.
Shanghai Fosun Pharmaceutical Group Co Ltd stock price is 24.12 CNY.
Shanghai Fosun Pharmaceutical Group Co Ltd stock price (24.12 CNY) is 40% less than its Intrinsic Value (40.28 CNY).
Shanghai Fosun Pharmaceutical Group Co Ltd stock price (24.12 CNY) is 10% less than its DCF Value (26.85 CNY). Open DCF Valuation
Shanghai Fosun Pharmaceutical Group Co Ltd stock price (24.12 CNY) is 55% less than its Relative Value (53.72 CNY). Open Relative Valuation
Shanghai Fosun Pharmaceutical Group Co Ltd has upside potential of 27% compared to the average analyst price target.
Open Wall St Estimates
Shanghai Fosun Pharmaceutical Group Co Ltd has positive Net Income for the last twelve months.
Shanghai Fosun Pharmaceutical Group Co Ltd has positive three-year average ROE (Return on Equity): 10%. The company is efficient at transforming stockholders' equity into net income.
Shanghai Fosun Pharmaceutical Group Co Ltd's short-term assets (34B CNY) exceed its short-term liabilties (34B CNY).
Shanghai Fosun Pharmaceutical Group Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 4% to 1%.
Shanghai Fosun Pharmaceutical Group Co Ltd has positive Net Debt. This means that the company has more debt (32B CNY) than cash and short-term investments (15B CNY).
Shanghai Fosun Pharmaceutical Group Co Ltd's Revenue has dropped by 6% over the past 12 months.
Shanghai Fosun Pharmaceutical Group Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 5%.
Shanghai Fosun Pharmaceutical Group Co Ltd's Revenue is forecast to grow at a rate of 8% per year over the next 3 years.
Shanghai Fosun Pharmaceutical Group Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 11% to 5%.
Shanghai Fosun Pharmaceutical Group Co Ltd has positive Operating Income for the last twelve months.
Shanghai Fosun Pharmaceutical Group Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 1%.
Shanghai Fosun Pharmaceutical Group Co Ltd's Revenue has been growing by 11% per year for the last 3 years.
Shanghai Fosun Pharmaceutical Group Co Ltd's long-term assets (113B CNY) exceed its long-term liabilties (68B CNY).
Shanghai Fosun Pharmaceutical Group Co Ltd has a very low three-year average ROIC (Return on Invested Capital): 3%. The company is not efficient at using invested capital to generate operating income.
Shanghai Fosun Pharmaceutical Group Co Ltd has negative Free Cash Flow for the last twelve months.
Shanghai Fosun Pharmaceutical Group Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.69.
Shanghai Fosun Pharmaceutical Group Co Ltd has positive Gross Profit for the last twelve months.
Shanghai Fosun Pharmaceutical Group Co Ltd's Altman Z-Score is very low and is equal to 1.34.
Valuation Backtest
Shanghai Fosun Pharmaceutical Group Co Ltd
Run backtest to discover the historical profit from buying and selling
Shanghai Fosun Pharmaceutical Group Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Shanghai Fosun Pharmaceutical Group Co Ltd
Balance Sheet Decomposition
Shanghai Fosun Pharmaceutical Group Co Ltd
| Current Assets | 33.8B |
| Cash & Short-Term Investments | 15.3B |
| Receivables | 9.7B |
| Other Current Assets | 8.8B |
| Non-Current Assets | 79.7B |
| Long-Term Investments | 25B |
| PP&E | 23.7B |
| Intangibles | 28.2B |
| Other Non-Current Assets | 2.8B |
| Current Liabilities | 33.8B |
| Accounts Payable | 5.5B |
| Accrued Liabilities | 2.3B |
| Short-Term Debt | 15.8B |
| Other Current Liabilities | 10.1B |
| Non-Current Liabilities | 34B |
| Long-Term Debt | 15.9B |
| Other Non-Current Liabilities | 18.1B |
Earnings Waterfall
Shanghai Fosun Pharmaceutical Group Co Ltd
|
Revenue
|
41.4B
CNY
|
|
Cost of Revenue
|
-21.7B
CNY
|
|
Gross Profit
|
19.7B
CNY
|
|
Operating Expenses
|
-18.4B
CNY
|
|
Operating Income
|
1.3B
CNY
|
|
Other Expenses
|
1.1B
CNY
|
|
Net Income
|
2.4B
CNY
|
Free Cash Flow Analysis
Shanghai Fosun Pharmaceutical Group Co Ltd
Profitability Score
Profitability Due Diligence
Shanghai Fosun Pharmaceutical Group Co Ltd's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Shanghai Fosun Pharmaceutical Group Co Ltd's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shanghai Fosun Pharmaceutical Group Co Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
Shanghai Fosun Pharmaceutical Group Co Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shanghai Fosun Pharmaceutical Group Co Ltd
According to Wall Street analysts, the average 1-year price target for
Shanghai Fosun Pharmaceutical Group Co Ltd
is 30.54 CNY
with a low forecast of 24.75 CNY and a high forecast of 39.9 CNY.
Shareholder Return
Price
Shanghai Fosun Pharmaceutical Group Co Ltd
| Average Annual Return | 16.67% |
| Standard Deviation of Annual Returns | 54.98% |
| Max Drawdown | -75% |
| Market Capitalization | 64.4B CNY |
| Shares Outstanding | 2 557 379 400 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Shanghai Fosun Pharmaceutical Group Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Shanghai Fosun Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shanghai, Shanghai and currently employs 36,279 full-time employees. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The firm's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The firm is also engaged in medical equipment and medical diagnosis business, as well as the provision of medical services. The company distributes its products primarily in domestic and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Shanghai Fosun Pharmaceutical Group Co Ltd
stock under the Base Case scenario is
40.28
CNY.
Compared to the current market price of 24.12 CNY,
Shanghai Fosun Pharmaceutical Group Co Ltd
is
Undervalued by 40%.
You don't have any saved screeners yet
